N-[2-(azetidin-3-yl)ethyl]-1,1,1-trifluoromethanesulfonamide | 1207178-10-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-[2-(azetidin-3-yl)ethyl]-1,1,1-trifluoromethanesulfonamide
• CAS: 1207178-10-6
• 化学式: C₆H₁₁F₃N₂O₂S
• 分子量: 232.227
• InChiKey: AYKOWFIIOAOQRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  N-[2-(azetidin-3-yl)ethyl]-1,1,1-trifluoromethanesulfonamide 、 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(2-(1-(4-chloro-2-(2-fluorophenylsulfonyl)phenylsulfonyl)azetidin-3-yl)ethyl)-1,1,1-trifluoromethanesulfonamide
  参考文献：
  名称：

  Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitors

  摘要：

  The triaryl bis-sulfone 1 was modified by converting the aryl A-ring to a piperidine ring. The piperidine ring was further elaborated to a spirocyclopropyl piperidine moiety. The effect on CB2 binding potency, rat calcium channel affinity, and CYP 2C9 inhibition is described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.084

文献信息

• Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligands
  作者：Ling Tong、B.B. Shankar、Lei Chen、Razia Rizvi、Joseph Kelly、Eric Gilbert、Chunli Huang、De-Yi Yang、Joseph A. Kozlowski、N.-Y. Shih、W. Gonsiorek、R. William Hipkin、Asra Malikzay、Charles A. Lunn、Daniel J. Lundell

  DOI：10.1016/j.bmcl.2010.08.126

  日期：2010.11

  We report further expansion of the structure activity relationship (SAR) on the triaryl bis sulfone class of compounds (I), which are potent CB2 receptor ligands with excellent selectivity over the CB1 receptor. This study was extended to B ring changes, followed by simultaneous optimization of the A-, B-, and C-rings. Compound 42 has excellent CB2 potency, selectivity and rat exposure. (C) 2010 Elsevier Ltd. All rights reserved.
• ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF
  申请人：INTEGRAL BIOSCIENCES PRIVATE LIMITED

  公开号：US20220135598A1

  公开（公告）日：2022-05-05

  The present invention discloses compounds useful in treatment of conditions associated with dysfunction of ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) enzyme. Specifically, the present invention discloses compound of formula (J) which exhibit inhibitory activity against ENPP1. Method of treating conditions associated with over-expression of ENPP1 gene with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.